pacemaker Qinming8631 DR (Qinming Medical, Baoji, China)	pacemaker Talos DR (Biotronik, Berlin, Germany)	The rate of adverse event	27011	27141	The rate of adverse event was 3.53% in the trial group and 2.67% in the control group, with no significant difference (P = 1.000).
pacemaker Qinming8631 DR (Qinming Medical, Baoji, China)	pacemaker Talos DR (Biotronik, Berlin, Germany)	The effective pacing rate immediately after the procedure	1750	1946	Effective pacing rates of trial and control groups were comparable both in the full analysis set and the per protocol set (81.4% vs. 79.5%, P = 0.712 and 95.4% vs. 89.5%, P = 0.143, respectively).
pacemaker Qinming8631 DR (Qinming Medical, Baoji, China)	pacemaker Talos DR (Biotronik, Berlin, Germany)	The stability of pacing during follow-up	25619	25771	The stability of pacing during follow-up was very high (99.0% in trial and 98.1% in control groups), and the difference was not significant (P = 0.621).
pacemaker Qinming8631 DR (Qinming Medical, Baoji, China)	pacemaker Talos DR (Biotronik, Berlin, Germany)	The effective sensitivity rate	25445	25618	The effective sensitivity rate immediately after the procedure was 94.8% and 93.6% in the trial and control groups, respectively, with no significant difference (P = 0.716).
pacemaker Qinming8631 DR (Qinming Medical, Baoji, China)	pacemaker Talos DR (Biotronik, Berlin, Germany)	The rate of adverse event	27011	27140	The rate of adverse event was 3.53% in the trial group and 2.67% in the control group, with no significant difference (P = 1.000)
pacemaker Qinming8631 DR (Qinming Medical, Baoji, China)	pacemaker Talos DR (Biotronik, Berlin, Germany)	The effective pacing rate immediately after the procedure	25294	25444	The effective pacing rate immediately after the procedure was no significant difference in the two groups (trial: 100% vs. control: 99.1%, P = 1.000).
